Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424

Article  PubMed  Google Scholar 

Islami F, Ferlay J, Lortet-Tieulent J et al (2017) International trends in anal cancer incidence rates. Int J Epidemiol 46:924–938

PubMed  Google Scholar 

Palefsky JM (1994) Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem. AIDS (Lond, Engl) 8:283–295

Article  CAS  Google Scholar 

Yhim HY, Lee NR, Song EK et al (2011) The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy. Int J Cancer 129:1752–1760

Article  CAS  PubMed  Google Scholar 

Gilbert DC, Williams A, Allan K et al (2013) p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy. Radiother Oncol 109:146–151

Article  CAS  PubMed  Google Scholar 

Ravenda PS, Magni E, Botteri E et al (2014) Prognostic value of human papillomavirus in anal squamous cell carcinoma. Cancer Chemother Pharmacol 74:1033–1038

Article  CAS  PubMed  Google Scholar 

Koerber SA, Schoneweg C, Slynko A et al (2014) Influence of human papillomavirus and p16(INK4a) on treatment outcome of patients with anal cancer. Radiother Oncol 113:331–336

Article  CAS  PubMed  Google Scholar 

Roldan Urgoiti GB, Gustafson K, Klimowicz AC et al (2014) The prognostic value of HPV status and p16 expression in patients with carcinoma of the anal canal. PLoS ONE 9:e108790

Article  PubMed  PubMed Central  Google Scholar 

Serup-Hansen E, Linnemann D, Skovrider-Ruminski W et al (2014) Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American joint committee on cancer stages I to III carcinoma of the anal canal. J Clin Oncol 32:1812–1817

Article  PubMed  Google Scholar 

Meulendijks D, Tomasoa NB, Dewit L et al (2015) HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. Br J Cancer 112:1358–1366

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baricevic I, He X, Chakrabarty B et al (2015) High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: different implications for vaccine prevention and prognosis. Eur J Cancer (Oxf, Engl: 1990) 51:776–785

Article  CAS  Google Scholar 

Nigro ND, Vaitkevicius VK, Considine B Jr (1974) Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 17:354–356

Article  CAS  PubMed  Google Scholar 

Ajani JA, Winter KA, Gunderson LL et al (2008) Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299:1914–1921

Article  CAS  PubMed  Google Scholar 

Peiffert D, Tournier-Rangeard L, Gerard JP et al (2012) Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 30:1941–1948

Article  CAS  PubMed  Google Scholar 

James RD, Glynne-Jones R, Meadows HM et al (2013) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol 14:516–524

Article  CAS  PubMed  Google Scholar 

Gunderson LL, Winter KA, Ajani JA et al (2012) Long-term update of US GI intergroup RTOG 98–11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 30:4344–4351

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamada K, Saiki Y, Komori K et al (2022) Characteristics of anal canal cancer in Japan. Cancer Med 11:2735–2743

Article  PubMed  PubMed Central  Google Scholar 

Takashima A, Shimada Y, Hamaguchi T et al (2009) Current therapeutic strategies for anal squamous cell carcinoma in Japan. Int J Clin Oncol 14:416–420

Article  PubMed  Google Scholar 

Ando H, Nishimura T, Nakamura T et al (2000) Chemoradiation therapy for squamous cell carcinoma of anal canal cancer: report of a case. Radiat Med 18:199–203

CAS  PubMed  Google Scholar 

Ito T, Takayanagi D, Sekine S et al (2023) Comparison of clinicopathological and genomic profiles in anal squamous cell carcinoma between Japanese and Caucasian cohorts. Sci Rep 13:3587

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ito Y, Hamaguchi T, Takashima A et al (2023) Definitive S-1/mitomycin-C chemoradiotherapy for stage II/III anal canal squamous cell carcinoma: a phase I/II dose-finding and single-arm confirmatory study (JCOG0903). Int J Clin Oncol 28:1063–1072

Article  CAS  PubMed  Google Scholar 

Munger K, Basile JR, Duensing S et al (2001) Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20:7888–7898

Article  CAS  PubMed  Google Scholar 

Jouhi L, Hagstrom J, Atula T et al (2017) Is p16 an adequate surrogate for human papillomavirus status determination? Curr Opin Otolaryngol Head Neck Surg 25:108–112

Article  PubMed  Google Scholar 

Welters MJ, de Jong A, van den Eeden SJ et al (2003) Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Can Res 63:636–641

CAS  Google Scholar 

de Jong A, van Poelgeest MI, van der Hulst JM et al (2004) Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Can Res 64:5449–5455

Article  Google Scholar 

Ishida Y, Agata Y, Shibahara K et al (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887–3895

Article  CAS  PubMed  PubMed Central  Google Scholar 

Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morris VK, Salem ME, Nimeiri H et al (2017) Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 18:446–453

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balermpas P, Martin D, Wieland U et al (2017) Human papilloma virus load and PD-1/PD-L1, CD8(+) and FOXP3 in anal cancer patients treated with chemoradiotherapy: rationale for immunotherapy. Oncoimmunology 6:e1288331

Article  PubMed  PubMed Central  Google Scholar 

Zhao YJ, Sun WP, Peng JH et al (2018) Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. Cancer Manag Res 10:1–11

Article  PubMed  Google Scholar 

Chamseddin BH, Lee EE, Kim J et al (2019) Assessment of circularized E7 RNA, GLUT1, and PD-L1 in anal squamous cell carcinoma. Oncotarget 10:5958–5969

Article  PubMed  PubMed Central  Google Scholar 

Mitra D, Horick NK, Brackett DG et al (2019) High IDO1 expression is associated with poor outcome in patients with anal cancer treated with definitive chemoradi